A pioneer in the field of Cancer Immunotherapy, emergence of PD-L1/PD-1 inhibitors and next generation therapies. Focused on the future of medicine and what's possible at the intersection between engineering, science and medicine.

Experienced drug developer (from pre-clinical through Phase I-IV), entrepreneur, executive- strong communicator and strategic leader with expertise in Oncology, Immunology, Large Molecule Engineering, Virology, Filings, Biomarkers and Building/Leading Organizations.